FDA Category 2 peptides: what the compounding rule actually changes

A recent TikTok from a compounding pharmacist claims that the FDA has moved on peptides, placing many in Category 2, which means compounding pharmacies are not supposed to produce them. The creator notes that despite this, peptides are everywhere, and predicts that will change. They also caution that quality peptide supply chains don't yet exist, so fast access is not the same as safe access.

What the clip is claiming

The video's core claim is that FDA's Category 2 designation will effectively halt compounding of certain peptides, yet the market is flooded with them. The pharmacist suggests that while enforcement may increase, a reliable, high-quality supply chain is still missing, so any immediate shift to compliant products is unlikely.

What the research neighborhood actually covers

The FDA's regulatory framework for compounding distinguishes between substances that are eligible for compounding (Category 1) and those that are not (Category 2) based on safety, efficacy, and public health need. Category 2 includes drugs that have been withdrawn or removed from the market for safety reasons, or that do not meet the criteria for compounding under section 503A of the FD&C Act. For peptides, this means many popular research peptides—like BPC-157, GHK-Cu, and others—may fall into Category 2 because they lack FDA-approved versions or sufficient safety data. The research literature on these peptides is largely preclinical, focusing on mechanisms like tissue repair (BPC-157), copper-dependent enzyme modulation (GHK-Cu), or metabolic pathways (NAD+). None of these have undergone the rigorous clinical trials needed for FDA approval as drug products.

Limits, missing context, and what a 15-second clip cannot show

A short video cannot capture the nuance of FDA rulemaking. The Category 2 designation does not automatically ban all compounding; it triggers a process where FDA can issue guidance, and states may enforce their own pharmacy boards. The clip also omits that some peptides may be moved to Category 1 if data emerges, or that compounding pharmacies can still legally produce peptides that are not on the Category 2 list. Moreover, the claim that 'supply chain doesn't exist' is an oversimplification—there are active pharmaceutical ingredient (API) manufacturers, but quality varies. The video also fails to distinguish between research-use peptides (RUO) and those intended for human use, which is a critical distinction for anyone buying from a catalog like ours.

How this maps to named research compounds

For researchers using our catalog, the FDA's move has no direct impact on RUO peptides. Compounds like BPC-157, GHK-Cu, NAD+, and TB-500 (Thymosin Beta-4) are sold for laboratory investigation only, not for human consumption. The regulatory debate centers on compounded human-use products, not on research chemicals. However, the clip's mention of 'quality peptides' aligns with our commitment to providing high-purity, batch-tested materials for scientific study. If you're using BPC-157 in animal models of wound healing, or GHK-Cu in cell culture studies on collagen synthesis, the FDA's stance on compounding doesn't change your protocols—but it does underscore the importance of sourcing from reputable suppliers who provide certificates of analysis.

Research-use caveat

All peptides in our catalog are intended for research purposes only, not for human or veterinary use. They are not approved by the FDA or any other regulatory body. Researchers must comply with institutional biosafety and animal care guidelines. The regulatory landscape for peptides is evolving, so stay informed, but always prioritize rigorous experimental design and ethical sourcing.

Open the full video fact-check page (transcript, takeaways, embedded clip).